Jie Lin Nai

Latham & Watkins - UNITED STATES


Jie Lin Nai's competencies

Practice Area Jurisdiction Rank Agg. Deals Value Clients Dimension N. of Transactions Last Quarter
Debt Capital MarketsUNITED STATES596150035001
Equity Capital MarketsUNITED STATES1078300882
Practice Area Jurisdiction Rank Agg. Deals Value Clients Dimension N. of Transactions Last Quarter

Client Reviews

The Client Reviews provides a qualitative rating based on Partners' Clients feedback assessment


Communication Skills

FusionCharts will load here.

Technical skills

FusionCharts will load here.

Efficiency

FusionCharts will load here.


Effectiveness

FusionCharts will load here.



Perceived Added Value

FusionCharts will load here.

Ranking 2022: Jie Lin Nai - Latham & Watkins

Practice Area Agg. Deals Value Clients Dimension N. of Transactions Tier
Equity Capital Markets300882
Practice Area Agg. Deals Value Clients Dimension N. of Transactions Tier

Ranking 2021: Jie Lin Nai - Latham & Watkins

Practice Area Agg. Deals Value Clients Dimension N. of Transactions Tier
Practice Area Agg. Deals Value Clients Dimension N. of Transactions Tier

Ranking 2020: Jie Lin Nai - Latham & Watkins

Practice Area Agg. Deals Value Clients Dimension N. of Transactions Tier
Practice Area Agg. Deals Value Clients Dimension N. of Transactions Tier

Significant Clients

The chart shows a balanced list of the Jie Lin Nai's client portfolio - based on PBV Monitor's Analyzed Transactions during last Twelve Mounths
FusionCharts XT will load here!

Team

The chart shows a balanced list of counselor working with Jie Lin Nai - based on PBV Monitor's analyzed transactions during last Twelve Mounths
FusionCharts XT will load here!

Co-Counsel

The Chart shows a balanced list of Jie Lin Nai's Co-Counsel Law Firm - based on PBV Monitor's analyzed transactions during last Twelve Mounths

Counterparts

The Chart shows a balanced list of Jie Lin Nai's other Firms involved - based on PBV Monitor's analyzed transactions during last Twelve Mounths
FusionCharts XT will load here!

Peer Reviews

The Peer Reviews provides a qualitative rating based on Counterparts / Referees' feedback assessment


FusionCharts will load here.

Recent experiences

ArriVent BioPharma's $175 Million Initial Public Offering2/2/2024
Immunovant’s US$450 Million Common Stock Financing10/4/2023
Rocket Pharmaceuticals’ $175 Million Public Offering9/23/2023
AlloVir’s $75 Million Common Stock Public Offering7/3/2023
RadNet’s $259.2 Million Common Stock Public Offering6/24/2023
Skyward Specialty's Secondary Offering of Common Stock6/21/2023
UGI Corporation's $500 Million Senior Notes Offering6/8/2023